Takeda strengthens patient offering in India via availability of Vedolizumab (Kynteles®). Takeda introduces innovative gastrointestinal portfolio for patients with Inflammatory Bowel Diseases (IBD)and Ulcerative Colitis and Crohn’s Disease. Kynteles®is likely
